NASDAQ:KALV

Kalvista Pharmaceuticals Stock Insider Trading

etoro logo Buy KALV
*Your capital is at risk
$26.95
+0.0100 (+0.0371%)
At Close: Jun 03, 2026

KalVista Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -42.42. In total, the insiders bought 1.17M and sold 342.12K KALV shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
-42.42
Buy 1.17M shares
Sell 342.12K shares
67% Buy Activity
Negligible or No Correlation
Sell Signal Medium Confidence
Mar 25, 2026

Analysis Breakdown:

  • Supported by a negative Insider Power Score of -42.42.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Feb 21, 2026
Buy
Restricted Stock Unit
M-Exempt
Piekos Brian
Chief Financial Officer
C-Suite Officer 5 000
Value: $134.8K
Feb 21, 2026
Buy
Common Stock
M-Exempt
Audhya Paul K.
Chief Medical Officer
Officer 6 250
Value: $168.4K
Feb 21, 2026
Buy
Restricted Stock Unit
M-Exempt
Audhya Paul K.
Chief Medical Officer
Officer 6 250
Value: $168.4K
Feb 21, 2026
Buy
Common Stock
M-Exempt
Palleiko Benjamin L
Chief Executive Officer
CEO / President 23 250
Value: $626.6K
Feb 21, 2026
Buy
Common Stock
M-Exempt
Piekos Brian
Chief Financial Officer
C-Suite Officer 5 000
Value: $134.8K
Feb 18, 2026
Sell
Common Stock
S-Sale
Yea Christopher
Chief Development Officer
Officer 1 109
Value: $16.6K
Feb 18, 2026
Sell
Common Stock
S-Sale
Audhya Paul K.
Chief Medical Officer
Officer 1 163
Value: $17.4K
Feb 18, 2026
Sell
Common Stock
S-Sale
Palleiko Benjamin L
Chief Executive Officer
CEO / President 1 038
Value: $15.6K
Feb 17, 2026
Buy
Restricted Stock Unit
M-Exempt
Yea Christopher
Chief Development Officer
Officer 1 774
Value: $26.6K
Feb 17, 2026
Buy
Common Stock
M-Exempt
Yea Christopher
Chief Development Officer
Officer 1 774
Value: $26.6K
Feb 17, 2026
Buy
Common Stock
M-Exempt
Palleiko Benjamin L
Chief Executive Officer
CEO / President 2 419
Value: $36.3K
Feb 17, 2026
Buy
Restricted Stock Unit
M-Exempt
Palleiko Benjamin L
Chief Executive Officer
CEO / President 2 419
Value: $36.3K
Feb 17, 2026
Buy
Common Stock
M-Exempt
Audhya Paul K.
Chief Medical Officer
Officer 2 419
Value: $36.3K
Feb 17, 2026
Buy
Restricted Stock Unit
M-Exempt
Audhya Paul K.
Chief Medical Officer
Officer 2 419
Value: $36.3K
Feb 12, 2026
Sell
Common Stock
S-Sale
Palleiko Benjamin L
Chief Executive Officer
CEO / President 3 354
Value: $52.7K
Feb 11, 2026
Buy
Common Stock
M-Exempt
Palleiko Benjamin L
Chief Executive Officer
CEO / President 7 120
Value: $110.4K
Feb 11, 2026
Buy
Restricted Stock Unit
M-Exempt
Palleiko Benjamin L
Chief Executive Officer
CEO / President 7 120
Value: $110.4K
Jan 16, 2026
Buy
Restricted Stock Unit
A-Award
Arif Bilal
Chief Operations Officer
Officer 49 000
Value: $715.4K
Jan 16, 2026
Buy
Restricted Stock Unit
A-Award
Sweeny Nicole
Chief Commercial Officer
Officer 100 000
Value: $1.46M
Jan 16, 2026
Buy
Restricted Stock Unit
A-Award
Piekos Brian
Chief Financial Officer
C-Suite Officer 100 000
Value: $1.46M
Jan 16, 2026
Buy
Restricted Stock Unit
A-Award
Audhya Paul K.
Chief Medical Officer
Officer 100 000
Value: $1.46M
Jan 16, 2026
Buy
Restricted Stock Unit
A-Award
Palleiko Benjamin L
Chief Executive Officer
CEO / President 325 000
Value: $4.75M
Dec 08, 2025
Sell
Common Stock
S-Sale
Palleiko Benjamin L
Chief Executive Officer
CEO / President 7 294
Value: $120.4K
Dec 06, 2025
Buy
Common Stock
M-Exempt
Palleiko Benjamin L
Chief Executive Officer
CEO / President 15 625
Value: $421.1K
Dec 06, 2025
Buy
Restricted Stock Unit
M-Exempt
Palleiko Benjamin L
Chief Executive Officer
CEO / President 15 625
Value: $421.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT KALVISTA PHARMACEUTICALS INC
KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed ...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE